NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.
Publication
, Journal Article
Hoppe, RT; Advani, RH; Ai, WZ; Ambinder, RF; Armand, P; Bello, CM; Benitez, CM; Chen, W; Dabaja, B; Daly, ME; Gordon, LI; Hansen, N; Khan, N ...
Published in: J Natl Compr Canc Netw
April 2022
Hodgkin lymphoma (HL) is an uncommon malignancy of B-cell origin. Classical HL (cHL) and nodular lymphocyte-predominant HL are the 2 main types of HL. The cure rates for HL have increased so markedly with the advent of modern treatment options that overriding treatment considerations often relate to long-term toxicity. These NCCN Guidelines Insights discuss the recent updates to the NCCN Guidelines for HL focusing on (1) radiation therapy dose constraints in the management of patients with HL, and (2) the management of advanced-stage and relapsed or refractory cHL.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
April 2022
Volume
20
Issue
4
Start / End Page
322 / 334
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Humans
- Hodgkin Disease
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Armand, P., Bello, C. M., … Sundar, H. (2022). NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw, 20(4), 322–334. https://doi.org/10.6004/jnccn.2022.0021
Hoppe, Richard T., Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Philippe Armand, Celeste M. Bello, Cecil M. Benitez, et al. “NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.” J Natl Compr Canc Netw 20, no. 4 (April 2022): 322–34. https://doi.org/10.6004/jnccn.2022.0021.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, et al. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw. 2022 Apr;20(4):322–34.
Hoppe, Richard T., et al. “NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022.” J Natl Compr Canc Netw, vol. 20, no. 4, Apr. 2022, pp. 322–34. Pubmed, doi:10.6004/jnccn.2022.0021.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Armand P, Bello CM, Benitez CM, Chen W, Dabaja B, Daly ME, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Johnston PB, Kaminski MS, Kelsey CR, Kenkre VP, Khan N, Lynch RC, Maddocks K, McConathy J, Metzger M, Morgan D, Mulroney C, Pullarkat ST, Rabinovitch R, Rosenspire KC, Seropian S, Tao R, Torka P, Winter JN, Yahalom J, Yang JC, Burns JL, Campbell M, Sundar H. NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. J Natl Compr Canc Netw. 2022 Apr;20(4):322–334.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
April 2022
Volume
20
Issue
4
Start / End Page
322 / 334
Location
United States
Related Subject Headings
- Oncology & Carcinogenesis
- Humans
- Hodgkin Disease
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis